

Francesco Ferrara

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2059166/francesco-ferrara-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53

papers

611

citations

16

h-index

22

g-index

84

ext. papers

905

ext. citations

3

avg, IF

6.13

L-index

#	Paper	IF	Citations
53	From HTA to HTCLA: The Clinic and Logistics to Support Health Technology Assessments.. <i>Hospital Pharmacy</i> , 2022 , 57, 5-6	1.1	3
52	Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia.. <i>Inflammopharmacology</i> , 2022 , 1	5.1	1
51	Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.. <i>Journal of Reproductive Immunology</i> , 2022 , 151, 103630	4.2	3
50	Remdesivir versus ritonavir/lopinavir in COVID-19 patients. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1249-1250	1.9	26
49	A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?. <i>Immunologic Research</i> , 2021 , 1	4.3	1
48	What will be the role of molnupiravir in the treatment of COVID-19 infection?. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 1-2	1.5	6
47	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. <i>Egyptian Heart Journal</i> , 2021 , 73, 103	1.3	
46	Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection. <i>Molecular Biology Reports</i> , 2021 , 49, 827	2.8	1
45	Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients. <i>Italian Journal of Medicine</i> , 2021 , 15,	0.5	12
44	Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021 , 1	3.4	1
43	Sars-Cov-2 and risk of antiviral drug resistance. <i>Irish Journal of Medical Science</i> , 2021 , 1	1.9	6
42	Remdesivir and COVID-19. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1237-1238	1.9	19
41	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 958-965	2.3	6
40	COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. <i>Irish Journal of Medical Science</i> , 2021 , 1	1.9	14
39	Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. <i>Respiratory Medicine</i> , 2021 , 178, 106322	4.6	26
38	Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. <i>Human Immunology</i> , 2021 , 82, 264-269	2.3	23
37	Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 983-988	2.3	10

36	Drugs acting on the renin-angiotensin system and SARS-CoV-2. <i>Drug Discovery Today</i> , 2021 , 26, 870-874	8.8	22
35	COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified. <i>Immunologic Research</i> , 2021 , 69, 115-116	4.3	
34	Scientific Hypothesis for Treatment of COVID-19 Lung Lesions by Adjusting ACE/ACE2 Imbalance. <i>Cardiovascular Toxicology</i> , 2021 , 21, 498-503	3.4	11
33	COVID-19 vaccination in pregnancy. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 1-2	1.5	1
32	Brief review of the mRNA vaccines COVID-19. <i>Inflammopharmacology</i> , 2021 , 29, 645-649	5.1	11
31	The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , 2021 , 394, 1589-1593	3.4	5
30	Logistics management provides greater efficiency, governance and compliance. <i>International Journal of Clinical Pharmacy</i> , 2021 , 43, 1431-1435	2.3	1
29	Plausible Positive Effects of Statins in COVID-19 Patient. <i>Cardiovascular Toxicology</i> , 2021 , 21, 781-789	3.4	5
28	COVID-19 vaccines and decreased transmission of SARS-CoV-2. <i>Inflammopharmacology</i> , 2021 , 29, 1357-1360	3.6	16
27	Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 156, 105579	5.1	28
26	Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1637-1638	1.9	21
25	The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. <i>Egyptian Liver Journal</i> , 2021 , 11, 11	1.6	16
24	Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021 , 2, 100056	3	0
23	Efficacy of synthetic glucocorticoids in COVID-19 endothelites. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , 2021 , 394, 1003-1007	3.4	28
22	Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. <i>Medical Hypotheses</i> , 2021 , 147, 110486	3.8	16
21	Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	3
20	Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. <i>Italian Journal of Medicine</i> , 2020 ,	0.5	12
19	Anti-rheumatic in SARS-CoV-2: benefit or risk?. <i>Italian Journal of Medicine</i> , 2020 ,	0.5	10

18	Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period?. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-2	2.7	1
17	Clinical Pharmacology Aspects in Patients Treated with TNF Inhibitors During SARS-Cov-2 Pandemic. <i>Advanced Pharmaceutical Bulletin</i> , 2020 , 11, 393-394	4.5	1
16	Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?. <i>Indian Journal of Pharmacology</i> , 2020 , 52, 441-442	2.5	13
15	The impact of COVID-19 in diabetic patient. <i>Archives of Medicine and Health Sciences</i> , 2020 , 8, 167	0.5	1
14	Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. <i>Life Sciences</i> , 2020 , 262, 118510	6.8	32
13	The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1615-1618	2.8	44
12	Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?. <i>European Journal of Pharmacology</i> , 2020 , 883, 173373	5.3	26
11	Correlation between the use of statins and COVID-19: what do we know?. <i>BMJ Evidence-Based Medicine</i> , 2020 ,	2.7	9
10	The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-5	2.7	12
9	Sacubitril, valsartan and SARS-CoV-2. <i>BMJ Evidence-Based Medicine</i> , 2020 ,	2.7	25
8	Antidiabetes Agents against Sars-Cov-2 Infection. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-4	2.7	1
7	COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-4	2.7	28
6	Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. <i>BMC Pharmacology & Toxicology</i> , 2018 , 19, 16	2.6	27
5	Identification of protein-protein interactions of human HtrA1. <i>Frontiers in Bioscience - Elite</i> , 2011 , 3, 1493-8	1.8	6
4	Acute Myeloid Leukemia Expressing T-Cell Antigens: Clinico-Hematological Report on Six Cases. <i>Leukemia and Lymphoma</i> , 1990 , 3, 217-22	1.9	8
3	Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?. <i>Hospital Pharmacy</i> , 001857872110690	1.1	0
2	The Role of Vitamin C in the Treatment of Sepsis. <i>Drugs and Therapy Perspectives</i> , 1	1.5	
1	Sacubitril/Valsartan and SARS-CoV-2		3

